Mylan N.V. (NASDAQ:MYL) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $4.30-4.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.12. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $12.46 billion.
Mylan N.V. (NASDAQ MYL) traded up 0.52% during trading on Friday, hitting $30.72. 7,185,271 shares of the company’s stock traded hands. The company’s 50 day moving average price is $36.12 and its 200 day moving average price is $38.80. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $49.09. The company has a market cap of $16.47 billion, a PE ratio of 24.83 and a beta of 1.27.
Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.18 by $0.08. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.16 earnings per share. Analysts expect that Mylan N.V. will post $4.52 earnings per share for the current year.
MYL has been the topic of a number of recent analyst reports. Barclays PLC upgraded Mylan N.V. from an equal weight rating to an overweight rating and lifted their target price for the stock from $47.00 to $50.00 in a research note on Monday, May 22nd. BMO Capital Markets initiated coverage on Mylan N.V. in a research note on Monday, May 1st. They set an outperform rating and a $50.00 target price on the stock. Cantor Fitzgerald initiated coverage on Mylan N.V. in a research note on Friday, June 16th. They set a neutral rating and a $41.00 target price on the stock. Royal Bank Of Canada set a $41.00 price objective on Mylan N.V. and gave the company a hold rating in a research note on Sunday, July 16th. Finally, Zacks Investment Research cut Mylan N.V. from a hold rating to a sell rating in a research note on Monday, May 15th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $47.73.
In related news, President Rajiv Malik sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the sale, the president now owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anthony Mauro sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by insiders.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.